It suggested that nor@MSC‐EVs may inhibit STAT3‐mediated Th17 activation,[32] offering a reasonable explanation for the observed reduction in splenomegaly of psoriasis mice (Figure 5G) and further hint at investigating the immunological modulation mechanism of nor@MSC‐EVs treatment for psoriasis. This evidence concerns the gene STAT3 and Splenomegaly.